AMGN רווח למניה בשנים עשר החודשים האחרונים Amgen Corp
High R&D costs and FDA oversight create significant barriers to entry, allowing Amgen Inc. (AMGN) to dictate premium pricing for unique biologics. The fundamental TTM net income per share metric in the price action on the GURU.Markets chart confirms this strategy, where the 17.17 mark reflects the current state. A stable staff of leading geneticists guarantees further growth in pipeline efficiency.
פילוחי מדדים פיננסיים ומדדי שוק עבור Amgen Corp (AMGN)
Amgen Inc. effective management of M&A and patent protection translates directly into sustainable profitability, as reflected by the trailing 12-month earnings per share. This indicator is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to assess the asset's real yield without issuance noise and avoid overpaying for an overheated stock.
